Osteoclast-rich lesions of bone: A clinical and molecular overview

Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition

Volumn , Issue , 2015, Pages 257-272

  Flanagan, Adrienne M ^a,b   Tirabosco, Roberto ^b   Gikas, Panagiotis D ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aneurysmal bone cyst; Cherubism; Chondroblastoma; Chondrosarcoma; Hyperparathyroidism; Noonan syndrome; Osteoclast rich bone lesions

Indexed keywords

EID: 84942766759     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-416721-6.00023-6     Document Type: Chapter

References (182)

1. Reid R, Banerjee SS, Sciot R. Giant cell tumor. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of Soft Tissue and Bone. Lyon: IARC Press; p. 310-312.
2. Behjati, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genetics 2013, 45:1479-1482.
3. Campanacci M., Baldini N., Boriani S. Giant-cell tumor of bone. J Bone Joint Surg (Am) 1987, 69:106-114.
4. Sung H.W., Kuo D.P., Shu W.P. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg (Am) 1982, 64:755-761.
5. Kransdorf M.J., Sweet D.E., Buetow P.C., et al. Giant cell tumor in skeletally immature patients. Radiology 1992, 184:233-237.
6. Picci P., Manfrini M., Zucchi V. Giant-cell tumor of bone in skeletally immature patients. J Bone Joint Surg (Am) 1983, 65:486-490.
7. Hoch B., Inwards C., Sundaram M., et al. Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases. J Bone Joint Surg (Am) 2006, 88:1998-2008.
8. Fain J.S., Unni K.K., Beabout J.W. Nonepiphyseal giant cell tumor of the long bones. Clinical, radiologic, and pathologic study. Cancer 1993, 71:3514-3519.
9. Bogumill G.S., Johnson L.C. Giant cell tumor: a metaphyseal lesion. J Bone Joint Surg (Am) 1972, 54:1558.
10. Goldenberg R.R., Campbell C., Bonfiglio M. Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg (Am) 1970, 52:619-664.
11. Campanacci M., Giunti A., Olmi R. Giant-cell tumours of bone: a study of 209 cases with long term follow up in 130 Italian. J Orthop Traumat 1975, 1:249-277.
12. McDonald D.J., Sim F., McLeod R.A., et al. Giant-cell tumor of bone. J Bone Joint Surg (Am) 1986, 68:235-242.
13. Albig W., et al. The human replacement histone H3.3B gene (H3F3B). Genomics 1995, 30:264-272.
14. Szenker E., Ray-Gallet D., Almouzni G. The double face of the histone variant H3.3. Cell Res 2011, 21:421-434.
15. Gessi M., et al. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?. J Neurooncol 2013, 112:67-72.
16. Gielen G.H., et al. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. Am J Clin Pathol 2013, 139:345-349.
17. Khuong-Quang D.A., et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012, 124:439-447.
18. Schwartzentruber J., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
19. Wu G., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012, 44:251-253.
20. Zhang J., et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013, 45:602-612.
21. de Souza P.E., Paim J.F., Carvalhais J.N., Gomez R.S. Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor. J Oral Pathol Med 1999, 28:54-58.
22. Pompetti F., Rizzo P., Simon R.M., Freidlin B., Mew D.J., Pass H.I., et al. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996, 63:37-50.
23. Ueda Y., Dockhorn-Dworniczak B., Blasius S., Mellin W., Wuisman P., Böcker W., et al. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 1993, 119:172-178.
24. Osaka S., Sugita H., Osaka E., Yoshida Y., Ryu J., Hemmi A., et al. Clinical and immuno- histochemical characteristics of benign giant cell tumour of bone with pulmonary metastases: case series. J Orthop Surg 2004, 12:55-62.
25. Lewis P.W., et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
26. Moskovszky L., Szuhai K., Krenács T., Hogendoorn P.C., Szendröi M., Benassi M.S., et al. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer 2009, 48:468-479.
27. Jaffe H.L., Lichtenstein L., Portis R. Giant CellTumor of Bone. Its Pathologic Appearance, Grading, Supposed Variants and Treatment. Arch Pathol 1940, 30:993.
28. Oliveira A.M., Perez-Atayde A.R., Inwards C.Y., et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 2004, 165:1773-1780.
29. Oliveira A.M., His B.L., Weremowicz S., et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res 2004, 64:1920-1923.
30. Kyriakos M. Benign fibrous histiocytoma of bone. World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of Soft Tissue and Bone 2002, 292-293. IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
31. Huang L., Teng X.Y., Cheng Y.Y., et al. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone 2004, 34:393-401.
32. Yoshida H., Hayashi S., Kunisada T., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
33. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
34. Sobacchi C., Frattini A., Guerrini M.M., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nature Genet 2007, 39:960-962.
35. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci 1999, 96:3540-3545.
36. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
37. Wong B.R., Josien R., Lee S.Y., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997, 186:2075-2080.
38. Yasuda H., Shima N., Nakagawa N.Y., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci 1998, 95:3597-3602.
39. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
40. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J Pathol 2000, 192:4-13.
41. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
42. Loser K., Mehling A., Loeser S., et al. Epidermal RANKL controls regulatory T cell numbers via activation of dendritic cells. Nat Med 2006, 1(2):1372-1379.
43. Fata J.E., Kong Y.Y., Li J., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
44. Hughes A.E., Ralston S.H., Marken J., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genet 2000, 24:45-48.
45. Whyte M.P., Obrecht S.E., Finnegan P.M., et al. Osteoprotegerin deficiency and juvenile Paget's disease. New Engl J Med 2002, 347:175-184.
46. West R.B., Rubin B.P., Miller M.A., et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci 2006, 103:690-695.
47. Saklatvala J., Pilsworth L.M., Sarsfield S.J., et al. Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein. Biochem J 1984, 224:461-466.
48. Brennan F.M., Chantry D., Jackson A., et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 2:244-247.
49. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
50. Ueki Y., Lin C.Y., Senoo M., et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 2007, 128:71-83.
51. Feldmann M., Maini R.A. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002, 69:12-18.
52. Kim N., Kadono Y., Takami M., et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005, 202:589-595.
53. Lam J., Takeshita S., Barker J.E., et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488.
54. Fuller K., Murphy C., Kirstein B., et al. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002, 143:1108-1118.
55. Zwerina J., Hayer S., Redlich K., et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthrit Rheum 2006, 54:463-472.
56. Yao Z., Li P., Zhang Q., et al. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 2006, 281:11846-11855.
57. Kitaura H., Zhou P., Kim H.J., et al. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005, 115:3418-3427.
58. Lovibond A.C., Haque S.J., Chambers T.J., et al. TGF-beta-induced SOCS3 expression augments TNF-alpha-induced osteoclast formation. Biochem Biophys Res Commun 2003, 309:762-767.
59. Zwerina J., Hayer S., Tohidast-Akrad M., et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthrit Rheum 2004, 50:277-290.
60. Roux S., Amazit L., Meduri G., et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002, 117:210-216.
61. James I.E., Dodds R.A., Lee-Rykaczewski E., et al. Purification and characterization of fully functional human osteoclast precursors. J Bone Min Res 1996, 11:1608-1618.
62. Flanagan A.M., Tinkler S.M., Horton M.A., et al. The multinucleate cells in giant cell granulomas of the jaw are osteoclasts. Cancer 1988, 62:1139-1145.
63. Flanagan A.M., Chambers T.J. Osteoclasts are present in the giant cell variant of malignant fibrous histiocytoma. J Pathol 1989, 159:53-57.
64. Joyner C.J., Quinn J.M., Triffitt J.T., et al. Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone. Bone Miner 1992, 16:37-48.
65. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
66. Gohda J., Akiyama T., Koga T., Takayanagi H., Tanaka S., Inoue J. RANK-mediated ampli- fication of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 2005, 24:790-799.
67. Ishida N., Hayashi K., Hoshijima M., Ogawa T., Koga S., Miyatake Y., et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002, 277:41147-41156.
68. Morgan T., Atkins G.J., Trivett M.K., Johnson S.A., Kansara M., Schlicht S.L., et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for re- ceptor activator of nuclear factor k{cyrillic}B. Am J Pathol 2005, 167:117-128.
69. Skubitz K.M., Cheng E.Y., Clohisy D.R., Thompson R.C., Skubitz A.P. Gene expression in giant-cell tumors. J Lab Clin Med 2004, 144:193-200.
70. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., et al. Es- sential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279:45969-45979.
71. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279:26475-26480.
72. Crotti T.N., Flannery M., Walsh N.C., Fleming J.D., Goldring S.R., McHugh K.P. NFATc1 regulation of the human β3 integrin promoter in osteoclast differentiation. Gene 2006, 372:92-102.
73. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269.
74. Nesbitt S., Nesbit A., Helfrich M., et al. Biochemical characterization of human osteoclast integrins. J Biol Chem 1993, 268:16737-16745.
75. Helfrich M.H., Nesbitt S.A., Lakkakorpi P.T., et al. Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption. Bone 1996, 19:317-328.
76. Horton M.A., Nesbitt S.A., Bennett J.H., et al. Integrins and other cell surface attachment molecules of bone cells. Principles of Bone Biology 2002, 265-286. Academic Press, San Diego, USA. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
77. Harms J.F., Welch D.R., Samant R.S., et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis 2004, 21:119-128.
78. Miller W.H., Alberts D.P., Bhatnagar P.K., et al. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 2000, 43:22-26.
79. Horton M.A., Massey H.M., Rosenberg R., et al. Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. Br J Haematol 2003, 122:950-957.
80. Blair H.C., Teitelbaum S.L., Tan H.L., et al. Passive chloride permeability charge coupled to H(+)-ATPase of avian osteoclast ruffled membrane. Am J Physiol 1991, 260:C1315-C1324.
81. Baron R., Neff L., Brown W., et al. Polarized secretion of lysosomal enzymes: co-distribution of cation-independent mannose-6-phosphate receptors and lysosomal enzymes along the osteoclast exocytic pathway. J Cell Biol 1988, 106:1863-1872.
82. Aboulafia A.J., Rosenbaum D.H., Sicard-Rosenbaum L. Treatment of large subchondral tumors of the knee with cryosurgery and composite reconstruction. Clin Orthop 1994, 307:189-199.
83. Campanacci M., Capanna R., Fabbri R. Curettage of giant cell tumor of bone. Reconstruction with subchondral grafts and cement. Chir Organi Mov 1990, 75:212-213.
84. Durr H.R., Maier M., Jansson V. Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol 1999, 25:610-618.
85. Mankin H.J., Fogelson F.S., Thrasher A.Z. Massive resection and allograft transplantation in the treatment of malignant bone tumors. New Engl J Med 1976, 294:1247-1255.
86. Malone S., O'Sullivan B., Catton C., et al. Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys 1995, 33:689-694.
87. Bennett C.J., Marcus R.B., Million R.R. Radiation therapy for giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1993, 26:299-304.
88. Nair M.K., Jyothirmayi R. Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1999, 43:1065-1069.
89. Feigenberg S.J., Marcus R.B., Scarborough M.T., et al. Radiation therapy for giant cell tumors of bone. Clin Ortho Rel Res 2003, 411:207-216.
90. Fidler MW Surgical treatment of giant cell tumours of the thoracic and lumbar spine: report of nine patients. Eur Spine J 2001, 10:69-77.
91. Lackman R.D., Khoury L.D., Esmail A., et al. The treatment of sacral giant-cell tumours by serial arterial embolisation. J Bone Joint Surg (Br) 2002, 84:873-877.
92. Flanagan A.M., Chambers T.J. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner 1989, 6:33-43.
93. Chang S.S., Suratwala S.J., Jung K.M., et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Ortho Rel Res 2004, 426:103-109.
94. Fujimoto N., Nakagawa K., Seichi A., et al. A new bisphosphonate treatment option for giant cell tumors. Oncol Rep 2001, 8:643-647.
95. Tse L.F., Wong K.C., Kumta S.M., Huang L., Chow T.C., Griffith J.F. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008, 42:68-73.
96. Balke, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer 2010, 10:462-470.
97. Cornelis F., Truchetet M.E., Amoretti N., Verdier D., Fournier C., Pillet O., et al. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long-term prospective study of tolerance and efficacy. Bone 2014, 58:11-16.
98. Thomas D., Henshaw R., Skubitz K., et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
99. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
100. Smith M.R., Saad F., Coleman R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379:39-46.
101. Branstetter D., Nelson S.D., Manivel J.C., Blay J.Y., Chawla S., Thomas D.M., et al. Denosumab induces tumor reduction and bone formation in patients with giant cell tumor of bone. Clin Cancer Res 2012, 18:4415-4424.
102. Van't Hof R.J., Idris A.I., Ridge S.A., et al. Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors. J Bone Min Res 2004, 19:1651-1660.
103. Idris A.I., Coste E., Greig I.R., Ralston S.H., van't Hof RJ The biphenyl-carboxylate derivative ABD328 is a novel orally active antiresorptive agent. Calcif Tissue Int 2010, 87(6):525-532.
104. Hoch B., Inwards C., Sundaram M., et al. Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases. J Bone Joint Surg (Am) 2006, 88:1998-2008.
105. Cummins C.A., Scarborough M.T., Enneking W.F. Multicentric giant cell tumor of bone. Clin Orthop 1996, 322:245-252.
106. Sim F.H., Dahlin D.C., Beabout J.W. Multicentric giant-cell tumor of bone. J Bone Joint Surg (Am) 1977, 59:1052-1060.
107. Hindman B.W., Seeger L.L., Stanley P. Multicentric giant cell tumor: report of five new cases. Skeletal Radiol 1994, 23:187-190.
108. Colby R.S., Saul R.A. Is Jaffe-Campanacci syndrome just a manifestation of neurofibromatosis type 1?. Am J Med Genet 2003, 123A:60-63.
109. Mirra J.M., Gold R.H., Rand F. Disseminated nonossifying fibromas in association with café-au-lait spots (Jaffe-Campanacci syndrome). Clin Ortho Rel Res 1982, 168:192-205.
110. Connell D., Munk P.L., Lee M.J., O'Connell J.X., Janzen D., Vu M., et al. Giant cell tumor of bone with selective metastases to mediastinal lymph nodes. Skeletal Radiol 1998, 27:341-345.
111. Tubbs W.S., Brown L.R., Beabout J.W. Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. Am J Roentgenol 1992, 158:331-334.
112. Maloney W.J., Vaughan L.M., Jones H.H. Benign metastasizing giant-cell tumor of bone. Report of three cases and review of the literature. Clin Orthop 1989, 243:208-215.
113. Cheng J.C., Johnston J.O. Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin Orthop 1997, 338:205-214.
114. Wulling M., Engels C., Jesse N., et al. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 2001, 127:467-474.
115. Alacacioglu A., Bengi G., Öztop I., Canda T., Balci P., Osma E., et al. Metastasis of giant cell tumor to the breast: case report and review of the literature. Tumori 2006, 92:351-353.
116. Zhang Q., Zhao H., Maheshwari A.V., Cai L., Yu F., Niu X. Isolated cardiac metastasis from a histologically "benign" giant-cell tumor of the distal end of the femur: a case report. J Bone Joint Surg Am 2010, 92:2725-2731.
117. Tyler W., Barrett T., Frassica F., McCarthy E. Skin metastasis from conventional giant cell tumor of bone: conceptual significance. Skeletal Radiol 2002, 31:166-170.
118. Connell D., Munk P.L., Lee M.J. Giant cell tumor of bone with selective metastases to mediastinal lymph nodes. Skeletal Radiol 1998, 27:341-345.
119. Sakkers R.J.B., Van der Heul R.O., Kroon H.M., et al. Late malignant transformation of a benign giant-cell tumor of bone. A case report. J Bone Joint Surg (Am) 1997, 79:259-262.
120. Chakravarti A., Spiro I.J., Hug E.B., et al. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg (Am) 1999, 81:1566-1573.
121. Sanerkin N.G., Mott M.G., Roylance J. An unusual intraosseous lesion with fibroblastic, osteoclastic, osteoblastic, aneurysmal and fibromyxoid elements. "Solid" variant of aneurysmal bone cyst. Cancer 1983, 51:2278-2286.
122. Unni K.K., Inwards C.W., Bridge J.A., et al. Tumors of the Bones and Joints 2005, American Registry of Pathology in collaboration with the AFIP, Washington, DC.
123. Panoutsakopoulos G., Pandis N., Kyriazoglou I., et al. Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts. Genes Chromosomes Cancer 1999, 26:265-266.
124. Dal Cin P., Kozakewich H.P., Goumnerova L., et al. Variant translocations involving 16q22 and 17p13 in solid variant and extraosseous forms of aneurysmal bone cyst. Genes Chromosomes. Cancer 2000, 28:233-234.
125. Sciot R., Dorfman H., Brys P., et al. Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions. A report from the CHAMP study group. Mod Pathol 2000, 13:1206-1210.
126. Oliveira A.M., Chou M.M., Perez-Atayde A.R., Rosenberg A.E. Aneurysmal bone cyst: a neoplasm driven by upregulation of the USP6 oncogene. J Clin Oncol 2006, 24(1):e1.
127. Amary M.F., Ye H., Berisha F., Tirabosco R., Presneau N., Flanagan A.M. Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. Virchows Arch 2013, 463(1):97-98.
128. Oliveira A.M., Perez-Atayde A.R., Dal Cin P., et al. Oncogene 2005, 24:3419-3426.
129. Pringle L.M., Young R., Quick L., et al. Atypical mechanism of NF-kappaB activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis. Oncogene 2012, 31:3525-3535.
130. Ye Y., Pringle L.M., Lau A.W., et al. TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB. Oncogene 2010, 29:3619-3629.
131. Vergel De Dios A.M., Bond J.R., Shives T.C., McLeod R.A., Unni K.K. Aneurysmal bone cyst. A clinicopathologic study of 238 cases. Cancer 1992, 69:2921-2931.
132. Marcove R.C., Sheth D.S., Takemoto S., et al. The treatment of aneurysmal bone cyst. Clin Ortho Rel Res 1995, 311:157-163.
133. Capanna R., Campanacci D.A., Manfrini M. Unicameral and aneurysmal bone cysts. Orthop Clin North Am 1996, 27:605-614.
134. Schreuder H.W., Veth R.P., Pruszczynski M. Aneurysmal bone cysts treated by curettage, cryotherapy and bone grafting. J Bone Joint Surg (Br) 1997, 79:20-25.
135. Cottalorda J., Bourelle S. Modern concepts of primary aneurysmal bone cyst. Arch Orthop Trauma Surg 2007, 127:105-114.
136. Feigenberg S.J., Marcus R.B., Zlotecki R.A., et al. Megavoltage radiotherapy for aneurysmal bone cysts. Int J Radiat Oncol Biol Phys 2001, 49:1243-1247.
137. Simm P.J., O'Sullivan M., Zacharin M.R. Successful treatment of a sacral aneurysmal bone cyst with zoledronic acid. J Pediatr Orthop 2013, 33:e61-e64.
138. Lange T., Stehling C., Frohlich B., Klingenhofer M., Kunkel P., Schneppenheim R., et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J 2013, 22:1417-1422.
139. Peeters S.P., Van der Geest I.C., de Rooy J.W., Veth R.P., Schreuder H.W. Aneurysmal bone cyst: The role of cryosurgery as local adjuvant treatment. J Surg Oncol 2009, 100(8):719-724.
140. Panoutsakopoulos G., Pandis N., Kyriazoglou I., et al. Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts. Genes Chromosomes Cancer 1999, 26:265-266.
141. Tartaglia M., Mehler E.L., Goldberg R., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genet 2001, 29:465-468.
142. Tartaglia M., Kalidas K., Shaw A., et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002, 70:1555-1563.
143. van Capelle C.I., Hogeman P.H.G., van der Sijs- Bos C.J.M., et al. Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatrs 2006, 166:905-909.
144. Martinez-Tello F.J., Manjon-Luengo P., Martin-Perez M., et al. Cherubism associated with neurofibromatosis type 1, and multiple osteolytic lesions of both femurs: a previously undescribed association of findings. Skeletal Radiol 2005, 34:793-798.
145. Krammer U., Wimmer K., Wiesbauer P., et al. Neurofibromatosis 1: a novel NF1 mutation in an 11-year-old girl with a giant cell granuloma. J Child Neurol 2003, 18:371-373.
146. Jafarov T. Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism. Clin Genet 2005, 68:190-191.
147. Reichenberger E.J., Flanagan A.M. Chapter Tumour syndromes. WHO Classification of tumours of soft tissue and bone 2013, Cherubism, Lyon. C.D.M. Fletcher, J. Bridge, P.C.W. Hogendoorn, F. Mertens (Eds.).
148. Mangion J., Rahman N., Edkins S., et al. The gene for cherubism maps to chromosome 4p16. 3. Am J Hum Genet 1999, 65:151-157.
149. Reichenberger E.J., Levine M.A., Olsen B.R., Papadaki M.E., Lietman S.A. The role of SH3BP2 in the pathophysiology of cherubism. Orphanet J Rare Dis 2012, 7(Suppl 1):S1-S5.
150. Papadaki M.E., Lietman S.A., Levine M.A., Olsen B.R., Kaban L.B., Reichenberger E.J. Cherubism: Best clinical practice. Orphanet J Rare Dis 2012, 7(Suppl 1):S1-S6.
151. Jones WA Familial multilocular cysts of the jaws. Am J Cancer 1933, 17:946-950.
152. Carvalho V.M., Perdigao P.F., Pimento P.M., et al. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism. J Oral Oncol 2007, 65:517-522.
153. Miha S.M., Hatani T., Qu X., et al. Point mutations of 3BP2 identified in human-inherited disease cherubism result in the loss of function. Genes Cells 2004, 9:993-1004.
154. de Lange J., van Maarle M.C., van den Akker H.P., et al. A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103:378-381.
155. Lo B., Faiyaz-Ul-Haque M., Kennedy S., et al. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Am J Med Genet 2003, 121:37-40.
156. Lietman S.A., Kalinchinko N., Deng X., et al. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Hum Mutat 2006, 27:717-718.
157. Imai Y., Kanno K., Moriya T., et al. A missense mutation in the SH3BP2 gene on chromosome 4p16.3 found in a case of nonfamilial cherubism. Cleft Palate Craniofac J 2003, 40:632-638.
158. Lietman S.A., Yin L., Levine M.A. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 2008, 371:644-648.
159. Mangion J., Edkins S., Goss A.N., et al. Familial craniofacial fibrous dysplasia: absence of linkage to GNAS1 and the gene for cherubism. J Med Genet 2000, 37:E37.
160. Thompson N Cherubism: Familial fibrous dysplasia of the jaws. Br J Plast Surg 1959, 12:89-103.
161. van Capelle C.I., Hogeman P.H.G., van der Sijs-Bos C.J.M., Heggelman B.G.F., Idowu B., Slootweg P.J., et al. Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatr 2007, 166(9):905-909.
162. Novack D.V., Faccio R. Jawing about TNF: new hope for cherubism. Cell 2007, 128:15-17.
163. Pagnini I., et al. Ineffectiveness of tumor necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism. Clin Exp Rheum 2011, 29(1):147.
164. Noordam C., Peer P.G., Francois I., De Schepper J., van den Burgt I., Otten B.J. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol 2008, 159:203-208.
165. Raaijmakers R., Noordam C., Karagiannis G., et al. Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database. J Pediatr Endocrinol Metab 2008, 21:267-273.
166. Dunlap C., Neville B., Vickers R.A., et al. The Noonan syndrome/cherubism association. Oral Pathol 1989, 67:698-705.
167. Cohen M.M.J., Gorlin R.J. Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet 1991, 40:159-166.
168. Tartaglia M., Pennacchio L.A., Zhao C., et al. Noonan-like/multiple giant cell lesion syndrome. Nature Genet 2007, 39:75-79.
169. Schubbert S., Zenker M., Rowe S.L., et al. Germline KRAS mutations cause Noonan syndrome. Nature Genet 2006, 38:331-336.
170. Roberts A.E., Araki T., Swanson K.D., et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007, 39:70-74.
171. Pandit P., Sarkozy A., Pennacchio L.A., et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nature Genet 2007, 39:1007-1012.
172. Razzaque M.A., Nishizawa T., Komoike Y., et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007, 39:1013-1017.
173. Beneteau C., Cavé H., Moncla A., Dorison N., Munnich A., Verloes A., et al. SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur J Hum Genet 2009, 17(10):1216-1221.
174. Hanna N., Parfait B., Talaat I.M., Vidaud M., Elsedfy H.H. SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome. Clin Genet 2009, 75(6):568-571.
175. Gorlin R.J., Anderson R.C., Blaw M. Multiple lentigenes syndrome. Am J Dis Child 1969, 117(6):652-662.
176. Easton D.F., Ponder M.A., Huson S.M., Ponder B.A. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993, 53(2):305-313.
177. Upadhyaya M., Huson S.M., Davies M., Thomas N., Chuzhanova N., Giovannini S., et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007, 80:140-151.
178. Ruggieri M., Pavone V., Polizz I.A., et al. Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999, 87:67-72.
179. Araki T., Mohi M.G., Ismat F.A., et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004, 10:849-857.
180. Schubbert S., Lieuw K., Rowe S.L., et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005, 106:311-317.
181. Largaespada D.A., Brannan C.I., Shaughnessy J.D., et al. The neurofibromatosis type 1 (NF1) tumor suppressor gene and myeloid leukemia. Curr Top Microbiol Immunol 1996, 211:233-239.
182. Yang F.C., Chen S., Robling A.G., et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 2006, 116:2880-2891.